Solutions
I knew from your references that you'd be able to handle our needs in Sacramento. What I didn't know was how easily you'd handle them, and how quickly. You know I'll be calling on you when we open in Billings, and in Philadelphia.

Joan Cameron. EVP, Edisen Isometrix
Reno, NV
Who knew how difficult it would be to navigate the tax code in my own town?! Fortunately, you knew, or rather you knew exactly how to set up our operations to actually take advantage of those regulations! We saved 13% that first year alone, and I'm so grateful for your help that I recommend your services to everyone I know. Thanks, you have a customer for life.

Bennett T. Jasper, CEO, Hiller-Jasper and Tennerman Ltd.
Eureka, CA
QualTek has expanded its IHC portfolio to include DNA based diagnostics for the verification and validation of existing candidate biomarkers that address the needs for integrating clinical medicine with techniques of modern molecular cell biology.
New Services
Biomarker discovery is a challenging central topic of current discussion in the field of medicine, primarily due to the changing landscape of therapies for treatment of a disease and their purported mechanism(s) of action, as well as the complex genetic interplay of a network of cellular signaling pathways.

QualTek provides custom genetic, epigenetic, SNP and microsatellite-based genotyping assays to establish pharmacogenetic ‘signatures’ that can further subclassify known pathologies (e.g., cancer), provide recurrence risk stratification necessary for improving clinical treatment options or be used as discovery targets contributing to the onset of human disease



  • KRAS mutations (typically codons G12, G13, Q61), BRAF mutation (typically E600) and PI3K subunit A mutation (typically E542, E545, H1047) yield constitutively active proteins in ~70% % of mCRC (metastatic colorectal cancer) and are associated with lack of response to EGFR inhibitors.

  • ASCO (The American Society of Clinical Oncology) and NCCN (The National Comprehensive Cancer Network) have issued recommendations for molecular testing of mCRC patients for KRAS mutation (but not BRAF or PI3KCA) prior to treatment with EGFR inhibitors.

  • At this time, there is no FDA approved molecular test for KRAS, BRAF or PI3KCA, and no specific methodology recommendations.

  • Detecting somatic mutations pose a greater analytical challenge than the detection of germline mutations, as these can be of low abundance within the background of wildtype sequence, which may only differ from mutant at a single nucleotide.

  • DNA sequencing, while being highly specific with a very low false positive rate, suffers from being a poorly sensitive technique for the identification of low abundance mutations.

  • At QualTek, low-prevalence somatic mutations, irrespective of type, are directly analyzed by DNA sequencing.

  • Our sensitive, specific, and reproducible DNA-based assays can identify single nucleotide changes to protein coding exons from KRAS, and BRAF and PI3KCA genes within as much as 99% wildtype background.


  More Detailed Information
email me
East Coast Laboratory
300 Pheasant Run   Newtown, PA 18940
West Coast Laboratory
6483 Calle Real, Suite A   Goleta, CA 93117
Molecular Pathology